Literature DB >> 16243920

Cardiomyocyte function associated with hyperactivity and/or hypertension in genetic models of LV hypertrophy.

Bradley M Palmer1, Zengyi Chen, Richard R Lachapelle, Edith D Hendley, Martin M LeWinter.   

Abstract

We examined cardiomyocyte intracellular calcium ([Ca2+]i) dynamics and sarcomere shortening dynamics in genetic rat models of left ventricular (LV) hypertrophy associated with or without hypertension (HT) and with or without hyperactive (HA) behavior. Previous selective breeding of the spontaneously hypertensive rat (SHR) strain, which is HA and HT, with the Wistar-Kyoto (WKY) rat strain, which is not hyperactive (NA) and not hypertensive (NT), has led to two unique strains: the WKHA strain, selected for HA and NT, and the WKHT strain, selected for NA and HT. Cardiomyocytes were isolated from young adult males and females of each strain, paced at 2, 3, and 4 Hz in 1.2 mM external Ca2+ concentration at 37 degrees C, and cardiomyocyte [Ca2+]i and sarcomere dynamics were recorded simultaneously. Under these conditions, LV cardiomyocyte systolic and diastolic [Ca2+]i dynamics and diastolic sarcomere dynamics in the WKHT were significantly enhanced compared with WKY controls, suggesting an underlying LV hypertrophic response that successfully compensated for HT in the absence of HA. LV cardiomyocyte [Ca2+]i dynamics in the WKHA and SHR were strikingly similar to each other and only slightly reduced compared with WKY. LV cardiomyocyte systolic and diastolic sarcomere dynamics, on the other hand, were significantly reduced in the SHR compare with WKHA and more so in male than in female SHR. We conclude from these data that HT alone is an insufficient descriptor of the cause of LV hypertrophy and diminished LV cardiomyocyte function in the SHR rat. These data further suggest that HA (augmented by male sex) in the SHR may interact with the HT state to initiate impaired cardiomyocyte function and thereby inhibit or undermine an otherwise compensatory response that may occur with HT in the absence of HA.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16243920     DOI: 10.1152/ajpheart.00310.2005

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  6 in total

1.  Erythropoietin induces positive inotropic and lusitropic effects in murine and human myocardium.

Authors:  David Hefer; Ting Yi; Donald E Selby; David E Fishbaugher; Sarah M Tremble; Kelly J Begin; Prospero Gogo; Martin M Lewinter; Markus Meyer; Bradley M Palmer; Peter Vanburen
Journal:  J Mol Cell Cardiol       Date:  2011-10-14       Impact factor: 5.000

2.  Cardiac myosin binding protein-C is essential for thick-filament stability and flexural rigidity.

Authors:  Lori R Nyland; Bradley M Palmer; Zengyi Chen; David W Maughan; Christine E Seidman; J G Seidman; Laurent Kreplak; Jim O Vigoreaux
Journal:  Biophys J       Date:  2009-04-22       Impact factor: 4.033

3.  Shortened conditioned eyeblink response latency in male but not female Wistar-Kyoto hyperactive rats.

Authors:  Alexandra Thanellou; Kira M Schachinger; John T Green
Journal:  Behav Neurosci       Date:  2009-06       Impact factor: 1.912

4.  Differential metal content and gene expression in rat left ventricular hypertrophy due to hypertension and hyperactivity.

Authors:  Meenakumari Subramanian; Adam L Hunt; Giuseppe A Petrucci; Zengyi Chen; Edith D Hendley; Bradley M Palmer
Journal:  J Trace Elem Med Biol       Date:  2014-02-22       Impact factor: 3.849

Review 5.  The Importance of Biological Sex and Estrogen in Rodent Models of Cardiovascular Health and Disease.

Authors:  Christa L Blenck; Pamela A Harvey; Jane F Reckelhoff; Leslie A Leinwand
Journal:  Circ Res       Date:  2016-04-15       Impact factor: 17.367

6.  Zinc-induced cardiomyocyte relaxation in a rat model of hyperglycemia is independent of myosin isoform.

Authors:  Ting Yi; Yaser Cheema; Sarah M Tremble; Stephen P Bell; Zengyi Chen; Meenakumari Subramanian; Martin M LeWinter; Peter VanBuren; Bradley M Palmer
Journal:  Cardiovasc Diabetol       Date:  2012-11-02       Impact factor: 9.951

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.